Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

BACKGROUND: Genetics-based basket trials have emerged to test targeted therapeutics across multiple cancer types. However, while vemurafenib is FDA-approved for BRAF-V600E melanomas, the non-melanoma basket trial was unsuccessful, suggesting mutation status is insufficient to predict response. We hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Carroll, Molly J., Parent, Carl R., Page, David, Kreeger, Pamela K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822426/
https://www.ncbi.nlm.nih.gov/pubmed/31672130
http://dx.doi.org/10.1186/s12885-019-6175-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822426/
https://www.ncbi.nlm.nih.gov/pubmed/31672130
http://dx.doi.org/10.1186/s12885-019-6175-2

Ejemplares similares